Table 5.

Mean 24-h ABPM and clinical blood pressure values in the imatinib, dasatinib and nilotinib groups.

	Imatinib25	Dasatinib9	Imatinib + dasatinib26	Nilotinib21	(Imatinib + dasatinib vs nilotinib) p
Clinical blood pressure
sBP	133.08 ± 19.82	133.44 ± 15.53	133.17 ± 18.59	138.59 ± 14.81	0.253
dBP	76.58 ± 8.38	80.44 ± 6.77	77.57 ± 8.09	82.36 ± 8.56	0.038
HR	73.50 ± 10.79	73.89 ± 11.40	73.60 ± 10.78	75.23 ± 13.42	0.616
ABPM 24 h
24 h
sBP	118.92 ± 9.62	120.33 ± 10.15	119.29 ± 9.62	129.00 ± 16.27	0.017
dBP	69.23 ± 6.78	72.44 ± 5	70.06 ± 6.46	73.45 ± 9.93	0.163
HR	69.46 ± 9.14	72.56 ± 9.36	70.26 ± 9.16	71.50 ± 12.24	0.664
Diurnal
sBP	122.31 ± 10.11	125.00 ± 10.67	123.00 ± 10.17	132.41 ± 16.49	0.022
dBP	71.58 ± 7.54	76.11 ± 5.67	72.74 ± 7.31	76.82 ± 10.87	0.130
HR	71.54 ± 10.18	73.78 ± 9.13	72.11 ± 9.84	72.23 ± 10.13	0.967
Nocturnal
sBP	111.23 ± 10.60	108.56 ± 10.38	110.54 ± 10.46	116.82 ± 16.55	0.084
dBP	62.58 ± 6.72	63.78 ± 4.78	62.89 ± 6.23	65.59 ± 8.83	0.181
HR	64.19 ± 8	68 ± 9.90	65.17 ± 8.54	65.64 ± 9.90	0.851
Dominant ABPM pattern (%)	Dipper (84%)	Dipper (100%)	Dipper (88.57%)	Dipper (90.90%)	0.617

Values highlighted in bold underline statistically significant results.

Mean 24-h ABPM and clinical blood pressure values are observed for groups of patients. Only the data of patients who have been with a single antineoplastic were collected.

The ABPM values are collected referring to the mean blood pressure values during 24 h, the mean values in the daytime period and the mean values in the night period. Data are compared between the imatinib + dasatinib and nilotinib treatment groups.

ABPM ambulatory blood pressure monitoring, CML chronic myeloid leukemia, dBP diastolic blood pressure, HR heart rate, sBP systolic blood pressure, TKI tirosin kinase inhibitors.